Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Buy
71
PEPG Quote, Financials, Valuation and Earnings
Last price:
$7.16
Seasonality move
:
14.31%
Day range:
$6.52 - $6.90
52-week range:
$0.88 - $7.80
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.88x
Volume:
492.8K
Avg. volume:
751.8K
1-year change:
85.87%
Market cap:
$470.2M
Revenue:
--
EPS (TTM):
-$2.84
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PEPG
PepGen Inc.
|
-- | -$0.37 | -- | -46.13% | $10.00 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
SRPT
Sarepta Therapeutics, Inc.
|
$380.6M | -$0.70 | -42.19% | -91.57% | $20.61 |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.37 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PEPG
PepGen Inc.
|
$6.84 | $10.00 | $470.2M | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$7.39 | $0.85 | $931.2M | 12.41x | $0.80 | 0% | 14.36x |
|
OGEN
Oragenics, Inc.
|
$0.87 | $2.00 | $715.9K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
SRPT
Sarepta Therapeutics, Inc.
|
$22.35 | $20.61 | $2.3B | 20.50x | $0.00 | 0% | 0.96x |
|
TOVX
Theriva Biologics, Inc.
|
$0.24 | $7.00 | $8.2M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PEPG
PepGen Inc.
|
9.66% | 3.509 | 5.49% | 12.95x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | -3.190 | 8.08% | 1.85x |
|
OGEN
Oragenics, Inc.
|
3.86% | 0.905 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
SRPT
Sarepta Therapeutics, Inc.
|
48.64% | -0.411 | 61.92% | 1.42x |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -2.522 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PEPG
PepGen Inc.
|
-$339K | -$18.7M | -69.46% | -80.35% | -- | -$19.4M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
SRPT
Sarepta Therapeutics, Inc.
|
$230.1M | -$62.9M | -10.24% | -20.67% | -15.75% | -$55.6M |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
PepGen Inc. vs. Competitors
-
Which has Higher Returns PEPG or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to PepGen Inc.'s net margin of -255.85%. PepGen Inc.'s return on equity of -80.35% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital PEPGPepGen Inc.-- -$0.52 $180.6M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About PEPG or NBY?
PepGen Inc. has a consensus price target of $10.00, signalling upside risk potential of 46.2%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -88.5%. Given that PepGen Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe PepGen Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PEPGPepGen Inc.5 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is PEPG or NBY More Risky?
PepGen Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.093, suggesting its less volatile than the S&P 500 by 90.725%.
-
Which is a Better Dividend Stock PEPG or NBY?
PepGen Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. PepGen Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PEPG or NBY?
PepGen Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. PepGen Inc.'s net income of -$18M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, PepGen Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 12.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PepGen Inc. is -- versus 14.36x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PEPGPepGen Inc.-- -- -- -$18M NBYNovaBay Pharmaceuticals, Inc.14.36x 12.41x $521K -$1.3M
-
Which has Higher Returns PEPG or OGEN?
Oragenics, Inc. has a net margin of -- compared to PepGen Inc.'s net margin of --. PepGen Inc.'s return on equity of -80.35% beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital PEPGPepGen Inc.-- -$0.52 $180.6M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About PEPG or OGEN?
PepGen Inc. has a consensus price target of $10.00, signalling upside risk potential of 46.2%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 129.89%. Given that Oragenics, Inc. has higher upside potential than PepGen Inc., analysts believe Oragenics, Inc. is more attractive than PepGen Inc..
Company Buy Ratings Hold Ratings Sell Ratings PEPGPepGen Inc.5 0 0 OGENOragenics, Inc.1 0 0 -
Is PEPG or OGEN More Risky?
PepGen Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.903, suggesting its less volatile than the S&P 500 by 9.685%.
-
Which is a Better Dividend Stock PEPG or OGEN?
PepGen Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PepGen Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PEPG or OGEN?
PepGen Inc. quarterly revenues are --, which are smaller than Oragenics, Inc. quarterly revenues of --. PepGen Inc.'s net income of -$18M is lower than Oragenics, Inc.'s net income of -$3.1M. Notably, PepGen Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PepGen Inc. is -- versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PEPGPepGen Inc.-- -- -- -$18M OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns PEPG or PTN?
Palatin Technologies has a net margin of -- compared to PepGen Inc.'s net margin of --. PepGen Inc.'s return on equity of -80.35% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PEPGPepGen Inc.-- -$0.52 $180.6M PTNPalatin Technologies-- -- -- -
What do Analysts Say About PEPG or PTN?
PepGen Inc. has a consensus price target of $10.00, signalling upside risk potential of 46.2%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than PepGen Inc., analysts believe Palatin Technologies is more attractive than PepGen Inc..
Company Buy Ratings Hold Ratings Sell Ratings PEPGPepGen Inc.5 0 0 PTNPalatin Technologies0 0 0 -
Is PEPG or PTN More Risky?
PepGen Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock PEPG or PTN?
PepGen Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PepGen Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PEPG or PTN?
PepGen Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. PepGen Inc.'s net income of -$18M is higher than Palatin Technologies's net income of --. Notably, PepGen Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PepGen Inc. is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PEPGPepGen Inc.-- -- -- -$18M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns PEPG or SRPT?
Sarepta Therapeutics, Inc. has a net margin of -- compared to PepGen Inc.'s net margin of -45.06%. PepGen Inc.'s return on equity of -80.35% beat Sarepta Therapeutics, Inc.'s return on equity of -20.67%.
Company Gross Margin Earnings Per Share Invested Capital PEPGPepGen Inc.-- -$0.52 $180.6M SRPTSarepta Therapeutics, Inc.57.63% -$1.80 $2.6B -
What do Analysts Say About PEPG or SRPT?
PepGen Inc. has a consensus price target of $10.00, signalling upside risk potential of 46.2%. On the other hand Sarepta Therapeutics, Inc. has an analysts' consensus of $20.61 which suggests that it could fall by -7.79%. Given that PepGen Inc. has higher upside potential than Sarepta Therapeutics, Inc., analysts believe PepGen Inc. is more attractive than Sarepta Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PEPGPepGen Inc.5 0 0 SRPTSarepta Therapeutics, Inc.7 14 3 -
Is PEPG or SRPT More Risky?
PepGen Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sarepta Therapeutics, Inc. has a beta of 0.485, suggesting its less volatile than the S&P 500 by 51.536%.
-
Which is a Better Dividend Stock PEPG or SRPT?
PepGen Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PepGen Inc. pays -- of its earnings as a dividend. Sarepta Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PEPG or SRPT?
PepGen Inc. quarterly revenues are --, which are smaller than Sarepta Therapeutics, Inc. quarterly revenues of $399.4M. PepGen Inc.'s net income of -$18M is higher than Sarepta Therapeutics, Inc.'s net income of -$179.9M. Notably, PepGen Inc.'s price-to-earnings ratio is -- while Sarepta Therapeutics, Inc.'s PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PepGen Inc. is -- versus 0.96x for Sarepta Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PEPGPepGen Inc.-- -- -- -$18M SRPTSarepta Therapeutics, Inc.0.96x 20.50x $399.4M -$179.9M
-
Which has Higher Returns PEPG or TOVX?
Theriva Biologics, Inc. has a net margin of -- compared to PepGen Inc.'s net margin of --. PepGen Inc.'s return on equity of -80.35% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital PEPGPepGen Inc.-- -$0.52 $180.6M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About PEPG or TOVX?
PepGen Inc. has a consensus price target of $10.00, signalling upside risk potential of 46.2%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 2785.41%. Given that Theriva Biologics, Inc. has higher upside potential than PepGen Inc., analysts believe Theriva Biologics, Inc. is more attractive than PepGen Inc..
Company Buy Ratings Hold Ratings Sell Ratings PEPGPepGen Inc.5 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is PEPG or TOVX More Risky?
PepGen Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.343, suggesting its less volatile than the S&P 500 by 65.729%.
-
Which is a Better Dividend Stock PEPG or TOVX?
PepGen Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PepGen Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PEPG or TOVX?
PepGen Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. PepGen Inc.'s net income of -$18M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, PepGen Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PepGen Inc. is -- versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PEPGPepGen Inc.-- -- -- -$18M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
69
RGC alert for Jan 7
Regencell Bioscience Holdings Ltd. [RGC] is up 58.95% over the past day.
Buy
69
WDC alert for Jan 7
Western Digital Corp. [WDC] is down 8.88% over the past day.
Buy
75
DRUG alert for Jan 7
Bright Minds Biosciences, Inc. [DRUG] is up 2.99% over the past day.
